Vor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX for a private placement of 5,338,078 shares of common stock at $14.05 per share, raising approximately $75.0 million in gross proceeds. The company intends to use the net proceeds to advance development of its clinical pipeline and for general corporate purposes.
Key takeaways
Vor Biopharma entered into a Securities Purchase Agreement with TCGX-affiliated investors on March 26, 2026.
The private placement involves the sale of 5,338,078 shares of common stock at $14.05 per share.
Gross proceeds from the offering are approximately $75.0 million.
The closing is expected to occur on March 30, 2026, subject to customary closing conditions.
Upon closing, the company will have 54,185,582 shares of common stock outstanding.
The company entered into a Registration Rights Agreement requiring it to file a registration statement within 30 days of closing.